Matthias Kappler

Matthias Kappler

Auto-generated profile, based on publicly available information

Matthias Kappler

Dr. von Hauner Children´s Hospital, University of Munich, German Center for Lung Research (DZL), Munich, Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2022 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MGMatthias Griese
Matthias Griese
MKMatthias Kappler
Matthias Kappler
FSFlorian Stehling
Florian Stehling
JSJohannes Schulze
Johannes Schulze
WBWinfried Baden
Winfried Baden
NSNicolaus Schwerk
Nicolaus Schwerk
Background: No results of controlled trials are available for any of the few treatments offered to children with interstitial lung diseases (chILD). We evaluated hydroxychloroquine (HCQ) in a phase 2, prospective, multicentre, 1:1-randomized, double-blind, placebo-controlled, parallel-group/crossover trial. HCQ (START arm) or placebo were given for 4 weeks. Then all subjects received HCQ for another 4 weeks. In the STOP arm subjects already taking HCQ were randomized to 12 weeks of HCQ or placebo (= withdrawal of HCQ). Then all subjects stopped treatment and were observed for another 12 weeks. Results: 26 subjects were included in the START arm, 9 in the STOP arm, of these four subjects participated in both arms. The primary endpoint, presence or absence of a response to treatment, assessed as oxygenation (calculated from a change in transcutaneous O2-saturation of ≥ 5%, respiratory rate ≥ 20% or level of respiratory support), did not differ between placebo and HCQ groups. Secondary endpoints including change of O2-saturation ≥ 3%, health related quality of life, pulmonary function and 6-min-walk-test distance, were not different between groups. Finally combining all placebo and all HCQ treatment periods did not identify significant treatment effects. Overall effect sizes were small. HCQ was well tolerated, adverse events were not different between placebo and HCQ. Conclusions: Acknowledging important shortcomings of the study, including a small study population, the treatment duration, lack of outcomes like lung function testing below age of 6 years, the small effect size of HCQ treatment observed requires careful reassessments of prescriptions in everyday practice (EudraCT-Nr.: 2013-003714-40, www.clinicaltrialsregister.eu, registered 02.07.2013). Registration The study was registered on 2 July 2013 (Eudra-CT Number: 2013-003714-40), whereas the approval by BfArM was received 24.11.2014, followed by the approval by the lead EC of the University Hospital Munich on 20.01.2015. At clinicaltrials.gov the trial was additionally registered on November 8, 2015 (NCT02615938).

12 November 2009 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
MKMatthias Kappler
Matthias Kappler
MFMaria Feilcke
Maria Feilcke
CSChristian Schröter
Christian Schröter
AKAngelika Kraxner
Angelika Kraxner
MGMatthias Griese
Matthias Griese

11 February 2022 in Thorax
Verified
Journal Article
Open access
PDF file
ESElias Seidl
Elias Seidl
NSNicolaus Schwerk
Nicolaus Schwerk
JCJulia Carlens
Julia Carlens
MWMartin Wetzke
Martin Wetzke
NENagehan Emiralioğlu
Nagehan Emiralioğlu
MGMatthias Griese
Matthias Griese
Introduction Acute exacerbations (AEs) increase morbidity and mortality of patients with chronic pulmonary diseases. Little is known about the characteristics and impact of AEs on children's interstitial lung disease (chILD). Methods The Kids Lung Register collected data on AEs, the clinical course and quality of life (patient-reported outcomes - PRO) of rare paediatric lung diseases. Characteristics of AEs were obtained. Results Data of 2822 AEs and 2887 register visits of 719 patients with chILD were recorded. AEs were characterised by increased levels of dyspnoea (74.1%), increased respiratory rate (58.6%) and increased oxygen demand (57.4%). Mostly, infections (94.4%) were suspected causing an AE. AEs between two register visits revealed a decline in predicted FEV1 (median −1.6%, IQR −8.0 to 3.9; p=0.001), predicted FVC (median −1.8%, IQR −7.5 to 3.9; p=0.004), chILD-specific questionnaire (median −1.3%, IQR −3.6 to 4.5; p=0.034) and the physical health summary score (median −3.1%, IQR −15.6 to 4.3; p=0.005) compared with no AEs in between visits. During the median observational period of 2.5 years (IQR 1.2–4.6), 81 patients died. For 49 of these patients (60.5%), mortality was associated with an AE. Conclusion This is the first comprehensive study analysing the characteristics and impact on the clinical course of AEs in chILD. AEs have a significant and deleterious effect on the clinical course and health-related quality of life in chILD.

23 October 2020 in Pediatric Pulmonology
Verified
Journal Article
Open access
PDF file
ESElias Seidl
Elias Seidl
JKJohanna Kramer
Johanna Kramer
FHFlorian Hoffmann
Florian Hoffmann
CSCarola Schön
Carola Schön
MGMatthias Griese
Matthias Griese
KRKarl Reiter
Karl Reiter
Background: Long segment laryngotracheoesophageal clefts (LTECs) are very rare large‐airway malformations. Over the last 40 years mortality rates declined substantially due to improved intensive care and surgical procedures. Nevertheless, long‐term morbidity, comorbidity, and clinical outcomes have rarely been assessed systematically.Methods: In this retrospective case series, the clinical presentation, comorbidities, treatment, and clinical outcomes of all children with long‐segment LTEC that were seen at our department in the last 15 years were collected and analyzed systematically.Results: Nine children were diagnosed with long segment LTEC (four children with LTEC type III and five patients with LTEC type IV). All children had additional tracheobronchial, gastrointestinal, or cardiac malformations. Tracheostomy for long‐time ventilation and jejunostomy for adequate nutrition was necessary in all cases. During follow‐up one child died from multiorgan failure due to sepsis at the age of 43 days. The clinical course of the other eight children (median follow‐up time 5.2 years) was stable. Relapses of the cleft, recurrent aspirations, and respiratory tract infections led to repeated hospital admissions.Conclusions: Long‐segment LTECs are consistently associated with additional malformations, which substantially influence long‐term morbidity. For optimal management, a multidisciplinary approach is essential.

1 June 2014 in Journal of Aerosol Medicine and Pulmonary Drug Delivery
Verified
Journal Article
Closed access
MGMatthias Griese
Matthias Griese
CEClaudia Eismann
Claudia Eismann
GBGerhard Börner
Gerhard Börner
ODOliver Denk
Oliver Denk
JSJörg Michael Schierholz
Jörg Michael Schierholz
MKMatthias Kappler
Matthias Kappler
Background: Improved inhalation device/drug combinations are necessary to advance inhaled antibiotic therapy in cystic fibrosis (CF). Previously, for a novel drug/inhaler combination, equivalent lung deposition was demonstrated; here, we investigated its safety and pharmacokinetics. Methods: In a randomized, open-labeled, multicenter, active controlled, parallel 28-day study, we compared a new tobramycin formulation (T100 PARI, 150 mg/1.5 mL) nebulized with a drug-specific PARI eFlow® nebulizer and TOBI® (300 mg/5 mL) nebulized with a PARI LC PLUS® nebulizer in 78 CF patients. Results: Noninferiority of the primary endpoint peak plasma tobramycin concentrations and the secondary endpoint area under the concentration time curves in plasma were observed. Sputum concentrations exceeded expected minimum inhibitory concentrations of Pseudomonas aeruginosa and were the same across both treatment groups, as were tolerability and safety. The nebulization time (4.6 vs. 16.1 min) was much shorter for the new drug/device combination. Conclusion: Inhaled therapy with T100 PARI delivered by an investigational eFlow offers a patient treatment time benefit and comparable safety and pharmacokinetics.

29 September 2026 in Chest
Verified
Journal Article
Open access
MGMatthias Griese
Matthias Griese
SMSrdjan Micic
Srdjan Micic
JCJulia Carlens
Julia Carlens
KMKatharina Mauß-Schwarzer
Katharina Mauß-Schwarzer
SBStella Bergemann
Stella Bergemann
ESElias Seidl
Elias Seidl